Log in to your Inderes Free account to see all free content on this page.
BioInvent International
29.05 SEK
+7.20 %
Less than 1K followers
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+7.20 %
-14.31 %
+1.04 %
-23.15 %
-24.55 %
-33.83 %
-19.75 %
-34.72 %
-96.95 %
BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.
Read moreMarket cap
1.91B SEK
Turnover
3.78M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.2.
2026
Annual report '25
29.4.
2026
Interim report Q1'26
29.4.
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors
EMA Positive Opinion for Orphan Drug Designation to BioInvent’s BI‑1808 for the Treatment of Cutaneous T-cell Lymphoma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
